Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORTOC: Oxymetazoline + Budesonide for Chronic Nasal Obstruction
NCT06830109Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Mucinex Full Force Nasal Spray in nasal obstruction (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Rate of Responders at 4 weeks. Started Oct 2024; status: recruiting.
02
Drugs
Mucinex Full Force Nasal Spray
03
Conditions
nasal obstruction
Beyond the preview
Go deeper on NCT06830109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830109.